Zydus gets COFEPRIS nod to market Bhava to treat various cancers EP News Bureau Jul 22, 2024 Bhava, a Bevacizumab biosimilar and will be marketed in different strengths of 100 mg/4 ml and 400 mg/16 ml
EMA approves Biocon’s new mAbs facility in India EP News Bureau Jun 24, 2024 EMA also renews GMP certifications for Biocon’s India and Malaysia sites
